Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosis

Deng Ho Yang, Tsay I. Chiang, I. Chang Chang, Fu Huang Lin, Cheng Chung Wei, Ya Wen Cheng

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Advanced glycation end-products (AGEs) can accumulate in organs and tissues during ageing and diabetes. Increased levels of AGEs are found in the bone tissue of patients with osteoporosis. The purpose of this study was to evaluate circulating AGEs in patients with osteoporosis. Methods: We evaluated plasma AGEs, osteoporosis-related biomarkers, and bone mass in 82 menopausal women with osteoporosis or osteopenia, 16 young women with osteopenia, and 43 healthy women without osteoporosis or osteopenia. Results: Higher levels of serum AGEs were found in the osteoporosis or osteopenia group compared to healthy women (P <0.0001). A negative correlation was observed between serum AGEs and lumbar spine bone density (BMD of lumbar spine, r = -0.249, P = 0.028; T-score of lumbar spine, r = -0.261, P = 0.021). Women with a increased level of serum AGEs (> 8.12 U/mL) had a 5.34-fold risk of osteopenia regarding lumbar spine T-score and a 3.31-fold risk of osteopenia regarding the hip T-score. Conclusion: Serum AGEs could be used to monitor the severity and progression of osteoporosis. An increased serum level of AGEs was associated with impaired bone formation and was a risk factor for the development of osteoporosis. Targeting AGEs may represent a novel therapeutic approach for primary or secondary osteoporosis.

Original languageEnglish
Pages (from-to)453-460
Number of pages8
JournalInternational Journal of Medical Sciences
Volume11
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Advanced Glycosylation End Products
Osteoporosis
Metabolic Bone Diseases
Serum
Bone and Bones
Osteogenesis
Hip
Spine
Biomarkers

Keywords

  • Advanced glycation end-products
  • Biomarker
  • Osteopenia
  • Osteopontin
  • Osteoporosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosis. / Yang, Deng Ho; Chiang, Tsay I.; Chang, I. Chang; Lin, Fu Huang; Wei, Cheng Chung; Cheng, Ya Wen.

In: International Journal of Medical Sciences, Vol. 11, No. 4, 2014, p. 453-460.

Research output: Contribution to journalArticle

Yang, Deng Ho ; Chiang, Tsay I. ; Chang, I. Chang ; Lin, Fu Huang ; Wei, Cheng Chung ; Cheng, Ya Wen. / Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosis. In: International Journal of Medical Sciences. 2014 ; Vol. 11, No. 4. pp. 453-460.
@article{2471f35eee064ec0b2afb6febdd0a97c,
title = "Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosis",
abstract = "Background: Advanced glycation end-products (AGEs) can accumulate in organs and tissues during ageing and diabetes. Increased levels of AGEs are found in the bone tissue of patients with osteoporosis. The purpose of this study was to evaluate circulating AGEs in patients with osteoporosis. Methods: We evaluated plasma AGEs, osteoporosis-related biomarkers, and bone mass in 82 menopausal women with osteoporosis or osteopenia, 16 young women with osteopenia, and 43 healthy women without osteoporosis or osteopenia. Results: Higher levels of serum AGEs were found in the osteoporosis or osteopenia group compared to healthy women (P <0.0001). A negative correlation was observed between serum AGEs and lumbar spine bone density (BMD of lumbar spine, r = -0.249, P = 0.028; T-score of lumbar spine, r = -0.261, P = 0.021). Women with a increased level of serum AGEs (> 8.12 U/mL) had a 5.34-fold risk of osteopenia regarding lumbar spine T-score and a 3.31-fold risk of osteopenia regarding the hip T-score. Conclusion: Serum AGEs could be used to monitor the severity and progression of osteoporosis. An increased serum level of AGEs was associated with impaired bone formation and was a risk factor for the development of osteoporosis. Targeting AGEs may represent a novel therapeutic approach for primary or secondary osteoporosis.",
keywords = "Advanced glycation end-products, Biomarker, Osteopenia, Osteopontin, Osteoporosis",
author = "Yang, {Deng Ho} and Chiang, {Tsay I.} and Chang, {I. Chang} and Lin, {Fu Huang} and Wei, {Cheng Chung} and Cheng, {Ya Wen}",
year = "2014",
doi = "10.7150/ijms.8172",
language = "English",
volume = "11",
pages = "453--460",
journal = "International Journal of Medical Sciences",
issn = "1449-1907",
publisher = "Ivyspring International Publisher",
number = "4",

}

TY - JOUR

T1 - Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosis

AU - Yang, Deng Ho

AU - Chiang, Tsay I.

AU - Chang, I. Chang

AU - Lin, Fu Huang

AU - Wei, Cheng Chung

AU - Cheng, Ya Wen

PY - 2014

Y1 - 2014

N2 - Background: Advanced glycation end-products (AGEs) can accumulate in organs and tissues during ageing and diabetes. Increased levels of AGEs are found in the bone tissue of patients with osteoporosis. The purpose of this study was to evaluate circulating AGEs in patients with osteoporosis. Methods: We evaluated plasma AGEs, osteoporosis-related biomarkers, and bone mass in 82 menopausal women with osteoporosis or osteopenia, 16 young women with osteopenia, and 43 healthy women without osteoporosis or osteopenia. Results: Higher levels of serum AGEs were found in the osteoporosis or osteopenia group compared to healthy women (P <0.0001). A negative correlation was observed between serum AGEs and lumbar spine bone density (BMD of lumbar spine, r = -0.249, P = 0.028; T-score of lumbar spine, r = -0.261, P = 0.021). Women with a increased level of serum AGEs (> 8.12 U/mL) had a 5.34-fold risk of osteopenia regarding lumbar spine T-score and a 3.31-fold risk of osteopenia regarding the hip T-score. Conclusion: Serum AGEs could be used to monitor the severity and progression of osteoporosis. An increased serum level of AGEs was associated with impaired bone formation and was a risk factor for the development of osteoporosis. Targeting AGEs may represent a novel therapeutic approach for primary or secondary osteoporosis.

AB - Background: Advanced glycation end-products (AGEs) can accumulate in organs and tissues during ageing and diabetes. Increased levels of AGEs are found in the bone tissue of patients with osteoporosis. The purpose of this study was to evaluate circulating AGEs in patients with osteoporosis. Methods: We evaluated plasma AGEs, osteoporosis-related biomarkers, and bone mass in 82 menopausal women with osteoporosis or osteopenia, 16 young women with osteopenia, and 43 healthy women without osteoporosis or osteopenia. Results: Higher levels of serum AGEs were found in the osteoporosis or osteopenia group compared to healthy women (P <0.0001). A negative correlation was observed between serum AGEs and lumbar spine bone density (BMD of lumbar spine, r = -0.249, P = 0.028; T-score of lumbar spine, r = -0.261, P = 0.021). Women with a increased level of serum AGEs (> 8.12 U/mL) had a 5.34-fold risk of osteopenia regarding lumbar spine T-score and a 3.31-fold risk of osteopenia regarding the hip T-score. Conclusion: Serum AGEs could be used to monitor the severity and progression of osteoporosis. An increased serum level of AGEs was associated with impaired bone formation and was a risk factor for the development of osteoporosis. Targeting AGEs may represent a novel therapeutic approach for primary or secondary osteoporosis.

KW - Advanced glycation end-products

KW - Biomarker

KW - Osteopenia

KW - Osteopontin

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84896456966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896456966&partnerID=8YFLogxK

U2 - 10.7150/ijms.8172

DO - 10.7150/ijms.8172

M3 - Article

VL - 11

SP - 453

EP - 460

JO - International Journal of Medical Sciences

JF - International Journal of Medical Sciences

SN - 1449-1907

IS - 4

ER -